What Is BPC-157? A Research Literature Overview

What follows covers what the molecule is, where its research record came from, what that record examines, and what it does not establish. Every figure quoted here belongs to a published paper and is cited. Figures that belong to a specific batch of material are a different category entirely, and those sit in the live batch registry against the lot they came from.

Nothing here describes use in people. The literature does not support that framing, and this article does not adopt it.

The molecule, and where the name came from

BPC-157 is a linear pentadecapeptide with a molecular weight of roughly 1419 daltons, placing it at the small end of the therapeutic peptide range. A 2026 narrative review in Pharmaceutics records that BPC stands for Body Protection Compound, the label given to a series of peptide fractions isolated and screened at the University of Zagreb in the early 1990s, and that the numeral identifies this sequence as the 157th candidate from that screening programme. The name is an index entry, not a description of anything the molecule was shown to do.

The sequence was first set out formally by Sikiric and colleagues in 1993, and a 2025 literature and patent review in Pharmaceuticals notes that it shows no sequence homology with known intestinal peptides.

Where the research record actually comes from

Volume and independence are different things, and BPC-157 research is a clear case of the two coming apart.

• One group produced most of it. By author affiliation analysis, more than 80 per cent of published BPC-157 studies originate from a single research group at the University of Zagreb. The internal consistency is high. Independent replication across other institutions is thin.
• The record is preclinical. A 2025 systematic review of the musculoskeletal literature identified 36 relevant studies. Thirty five were preclinical. One was a small retrospective clinical analysis.
• Dose response was never built. Virtually all preclinical work uses a single dose level, which means no minimum effective concentration, no maximum tolerated dose and no therapeutic window has been established.
• Rodents dominate. Species differences in proteolytic activity and renal clearance matter more for peptides than for small molecules, so rodent results carry limited predictive weight.

What the published literature examines

Three domains account for most of it. The gastrointestinal tract, being where the parent fraction was isolated, is the oldest and most heavily documented. Musculoskeletal work is the largest single body, run in rodent models of tendon transection, ligament injury, muscle laceration and fracture. Central nervous system work is smaller and entirely preclinical.

On mechanism, the candidate targets most consistently reported are vascular endothelial growth factor receptor 2, the early growth response gene Egr-1, and the nitric oxide system. Increased VEGFR-2 expression has been reported in rat hind limb ischaemia models and in endothelial cell cultures, which is to say in vivo animal work and in vitro work respectively. Neither is a human finding.

One absence is worth stating plainly. After three decades of investigation, no high-affinity receptor binding site for BPC-157 has been identified. Without a characterised binding site, the standard receptor occupancy framework used to model dose and response cannot be applied at all.

What the record does not establish

This is the section that most BPC-157 research summaries leave out, and it is the one that determines how much weight the rest can carry.

• No approved formulation and no validated dosing regimen. The 2026 Pharmaceutics review states directly that no pharmaceutical-grade formulation has been developed or validated, and that no Phase II clinical trial has been completed.
• The human dataset is very small. Available clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies, none using standardised pharmaceutical preparations.
• The one registered trial reported nothing. A Phase I study opened in 2015 in 42 healthy volunteers to establish safety and pharmacokinetics. Submission of results was cancelled the following year.
• Pharmacokinetics are animal data. The only formal ADME study was conducted in Sprague-Dawley rats and beagle dogs. Elimination half-life of the parent peptide was under 30 minutes in both. Absolute intramuscular bioavailability was 14 to 19 per cent in rats and 45 to 51 per cent in dogs.
• That species gap is the point. A threefold difference in bioavailability between two preclinical species tells you how little the animal numbers can predict about a third species.

None of this makes the preclinical work worthless. It does mean the honest description of BPC-157 is a compound with a substantial animal literature and an undeveloped clinical one, and any page that skips the second half is selling rather than explaining. That is one of the checks in what makes a UK peptide supplier trustworthy.

Where BPC-157 sits under UK rules

Two separate frameworks apply, and they answer different questions.

The first is medicines law. Regulation 46 of the Human Medicines Regulations 2012 prohibits selling, supplying or offering to supply an unauthorised medicinal product. BPC-157 holds no UK marketing authorisation, which is why it cannot lawfully be supplied here as a medicine. Whether a given product falls inside that definition turns on presentation and intended use rather than on the molecule alone, which is the subject of the legality of BPC-157 in the UK and, more broadly, of the MHRA position on research peptides.

MHRA borderline guidance sets out what it weighs when deciding: the explicit and implicit claims made, the pharmacological properties of the ingredients, the primary intended purpose, and how the product is presented through labelling, promotional literature, websites, social media and customer reviews. Presentation is assessed as a whole, which is why research use only terms have to be reflected in how a site writes, not just in a footer.

The second framework is anti-doping, and it is not the same question. UK Anti-Doping recorded BPC-157 as listed under S0, Non-approved Substances, when the 2022 Prohibited List took effect. S0 captures substances with no approval for human therapeutic use from any regulator, so the same absence of clinical development described above is precisely what places it there.

Reading a BPC-157 page critically

Most of what circulates about this compound converts animal findings into human statements somewhere between the abstract and the product description. The tell is usually grammatical rather than technical.

• Study type named in the sentence, not buried in a reference list
• Animal and human findings kept in separate sentences
• Citations that open, rather than author names with no link
• Limits stated as plainly as findings
• Any purity figure attached to a lot number, never to the catalogue
• An analytical certificate you can retrieve for the specific vial

That last pair is where a supplier’s claims become checkable rather than assertable. Understanding what the figure on a certificate measures is covered in how to read a peptide certificate of analysis and in what a purity percentage actually means, and the methods behind it in how a peptide is checked for purity. Who may order research materials in the first place is set out in the guidance on buying research peptides in the UK.

If you want to see how that works in practice rather than in principle, take the lot number from a BPC-157 listing and look it up in the batch registry. The certificate returned belongs to that specific batch, with its method and its date on it, which is the only form in which an analytical figure means anything.

Frequently asked questions